“Compromised” peer review hits three papers from Nature Publishing Group

company-info-big

Nature Publishing Group is retracting three papers today, after an investigation found evidence the peer-review process had been compromised.

The publisher issued a statement saying they had notified corresponding authors and institutions associated with the three papers, which were all published last year in the journals Cancer Gene Therapy and Spinal Cord. 

Here’s the note that’s going on each of the papers, (they’re the same, except for the publication date):

Continue reading “Compromised” peer review hits three papers from Nature Publishing Group

Fifth retraction for Wayne State researcher who fudged figures

teresita
Teresita L. Briones

Another retraction has appeared for Teresita Briones, who used to study neuroscience at Wayne State University — the final of five papers flagged by the Office of Research Integrity for containing falsified data.

According to the ORI notice published in May, Briones “intentionally, knowingly, and recklessly engaged in research misconduct by falsifying and/or fabricating data.” This latest paper to be retracted, which looks at the role of specific receptor in chronic inflammation of nervous tissue in rats, has two figures that “were duplicated, reused and falsely relabelled, and claimed to represent different experiments,” according to the retraction note.

The retraction note for “Chronic neuroinflammation and cognitive impairment following transient global cerebral ischemia: role of fractalkine/CX3CR1 signaling,” published in the Journal of Neuroinflammation, specifies the problematic figures:

Continue reading Fifth retraction for Wayne State researcher who fudged figures

“The peer review process was compromised”: Inflammation drug paper pulled

12

A paper that screened for antibodies that target TNFα, a major source of inflammation, has been retraction after an investigation revealed the peer-review process may have been compromised.

We’ve seen the peer review process “compromised” in a handful of ways — from a mathematician who oversaw the process on several of his own papers, to some 250 papers subject to outright fake peer review. The note for this paper, published in Amino Acids, doesn’t go into details, so we can only wonder what happened in this particular case.

Here’s the note for “Structure‑based development and optimization of therapy antibody drugs against TNFα:”

Continue reading “The peer review process was compromised”: Inflammation drug paper pulled

PLOS ONE issues editor’s note over controversial chronic fatigue syndrome research

Screen Shot 2015-12-15 at 11.42.08 PM

After a request for the original data was denied, PLOS ONE editors have flagged a 2012 sub analysis of a controversial clinical trial on chronic fatigue syndrome with an editor’s note.

The editor’s note — which reads like an Expression of Concern — reiterates the journal’s policy that authors make data and materials available upon request, and notes that staff are following up on “concerns” raised about the study.

There have been numerous requests for data from the “PACE” trial, as the clinical trial is known, which the authors say they have refused in order to protect patient confidentiality. On November 13, James Coyne, a psychologist at the University Medical Center, Groningen, submitted a request for the data from the PLOS ONE paper to King’s College London, where some of the authors were based. According to Coyne’s WordPress blog (he also has a blog hosted by PLOS), the journal asked him to let them know if he “had any difficulties obtaining the data.” He did — KCL denied the request last Friday (the whole letter is worth reading):

The university considers that there is a lack of value or serious purpose to your request. The university also considers that there is improper motive behind the request. The university considers that this request has caused and could further cause harassment and distress to staff.

Last author Peter White at Queen Mary University of London, UK, told us the journal had not asked them to release the data, but he would work with PLOS to address any questions:

We understand PLOS One are following up concerns expressed about the article, according to their internal processes. We will be happy to work with them to address any queries they might have regarding the research.

Here’s the editor’s note for “Adaptive Pacing, Cognitive Behaviour Therapy, Graded Exercise, and Specialist Medical Care for Chronic Fatigue Syndrome: A Cost-Effectiveness Analysis,” in full:

Continue reading PLOS ONE issues editor’s note over controversial chronic fatigue syndrome research

Authors retract abstract following misconduct by diabetes biotech

1Earlier this year, authors retracted a meeting abstract about a diabetes drug, following the revelation that the biotech that funded the trial committed misconduct.

The retraction was initiated by corresponding author Itamar Raz, at Hadassah Medical Center in Israel. The journal didn’t receive a response from any co-authors who were affiliated with the biotech company, Andromeda, so they were not included in the retraction process.

A few months after Hyperion Therapeutics acquired Andromeda’s diabetes drug DiaPep277, Hyperion announced it had evidence that some employees of Andromeda had “engaged in serious misconduct,” such as using un-blinded data and manipulating the analyses. Two relevant studies on the drug, designed to block the immune response that leads to type 1 diabetes, were retracted last year.

Here’s the retraction note for the abstract “Abstracts of the 50th Annual Meeting of the EASD, Vienna 2014. ‘Evaluation of DiaPep277® treatment in type 1 diabetes by integrated analysis,’” published in the May issue of the journal:

Continue reading Authors retract abstract following misconduct by diabetes biotech

7th retraction for heart researcher who faked patient records

1.coverAnna Ahimastos, a heart researcher who faked patient records, has notched her 7th retraction.

One more paper is expected to be retracted, according to a spokesperson from her former institution, the Baker IDI Heart & Diabetes Institute in Australia.

As with the other retractions, the 2005 paper in Hypertension — about how the hypertension drug ramipril may help alleviate cardiovascular disease — is being pulled after Ahimastos admitted to scientific misconduct. She asserts the data remain valid, and has not signed the retraction notice.

The Hypertension paper has been cited 63 times, according to Thomson Scientific’s Web of Knowledge. Here’s the retraction note in full (the language will be familiar to readers who have been following this case):

Continue reading 7th retraction for heart researcher who faked patient records

Authors lied about ethics approval for study on obesity, depression

cover (1)

Obesity has retracted a study that suggested overweight people may be less depressed than their slimmer counterparts in cultures where fat isn’t stigmatized, after realizing the authors lied about having ethical approval to conduct the research.

The authors claimed their research protocol had been approved by Norwegian and Bangladeshi ethical committees, but, according to the retraction note, part of the study “was conducted without the required approval of the university ethics board.” The journal’s managing editor told us that there is no evidence that there was harm to the study subjects.

Here’s more from the retraction note for “In Bangladesh, overweight individuals have fewer symptoms of depression than nonoverweight individuals:”

Continue reading Authors lied about ethics approval for study on obesity, depression

Five years after a retraction, company’s stock is up more than 500%

wntloggawntresearchwebny1Is ethical behavior good for business?

Five years ago this month, Swedish pharmaceutical company WntResearch immediately notified shareholders when authors retracted a 2009 Proceedings of the National Academy of Sciences (PNAS) paper on a potential cancer therapy that was key to the company’s business.

At the time, the company’s decision to disclose the retraction hurt its finances, as WntResearch delayed its planned initial public offering for three weeks. It also offered investors and shareholders the opportunity to withdraw their shares of WntResearch stock.

But, aside from one of the paper’s co-authors, “No one did that,” Nils Brünner, WntResearch’s CEO, told us. Since the company’s IPO on December 17, 2010, its stock price has increased from Continue reading Five years after a retraction, company’s stock is up more than 500%

Investigation into CT scan paper reveals plagiarism

Screen Shot 2015-12-01 at 10.02.20 AMA paper on the quality of computed tomography (CT) images of the human body didn’t stand up to a close examination. It’s been retracted after an investigation found that it plagiarized work from two publications and a poster by another researcher.

The text in the Journal of the Korean Physical Society paper was taken from work by Kenneth Weiss, a radiologist at the University of Miami, and Jane Weiss, CFO of the couple’s medical imaging company. According to emails that Jane Weiss forwarded to us, Kenneth Weiss brought the plagiarism to light after a PhD student pointed out the similarities between the JKPS paper and one of Weiss’s in the American Journal of Roentgenology. Weiss notified the AJR in January. They started an investigation into the matter, and alerted the JKPS.

The retraction note for “Measurement of image quality in CT images reconstructed with different kernels” provides more details about the investigation:

Continue reading Investigation into CT scan paper reveals plagiarism

Plagiarized figure hurts arthritis paper

Screen Shot 2015-12-03 at 10.49.37 AM

A paper on a way to inhibit arthritis has been retracted following an investigation confirming that it plagiarizes a figure from another paper on the same topic.

The paper, “Blockade of 11β-hydroxysteroid dehydrogenase type 1 enzyme inhibits experimental collagenase-induced osteoarthritis,” was published in Molecular Medicine Reports. A figure claims to show cartilage treated with a specific inhibitor:

Screen Shot 2015-12-03 at 12.06.56 PM

The retraction note tells us that the authors reproduced the figure from another paper in Inflammation — which describes a different inhibitor:

Continue reading Plagiarized figure hurts arthritis paper